Your browser doesn't support javascript.
loading
Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.
Rimoin, Anne W; Lu, Kai; Bramble, Matthew S; Steffen, Imke; Doshi, Reena H; Hoff, Nicole A; Mukadi, Patrick; Nicholson, Bradly P; Alfonso, Vivian H; Olinger, Gerrard; Sinai, Cyrus; Yamamoto, Lauren K; Ramirez, Christina M; Okitolonda Wemakoy, Emile; Kebela Illunga, Benoit; Pettitt, James; Logue, James; Bennett, Richard S; Jahrling, Peter; Heymann, David L; Piot, Peter; Muyembe-Tamfum, Jean Jacques; Hensley, Lisa E; Simmons, Graham.
Affiliation
  • Rimoin AW; Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles.
  • Lu K; Blood Systems Research Institute, and Department of Laboratory Medicine, University of California, San Francisco.
  • Bramble MS; Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles.
  • Steffen I; Department of Genetic Medicine Research, Children's Research Institute, Children's National Medical Center, Washington, District of Columbia.
  • Doshi RH; Blood Systems Research Institute, and Department of Laboratory Medicine, University of California, San Francisco.
  • Hoff NA; Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles.
  • Mukadi P; Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles.
  • Nicholson BP; Institut National de Recherche Biomedicale, Kinshasa, DRC.
  • Alfonso VH; Institute for Medical Research, Durham Veterans Affairs Medical Center, North Carolina.
  • Olinger G; Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles.
  • Sinai C; Integrated Research Facility at Fort Detrick.
  • Yamamoto LK; Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland.
  • Ramirez CM; Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles.
  • Okitolonda Wemakoy E; Blood Systems Research Institute, and Department of Laboratory Medicine, University of California, San Francisco.
  • Kebela Illunga B; Department of Biostatistics, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles.
  • Pettitt J; Kinshasa School of Public Health, Kinshasa.
  • Logue J; Direction de la Lutte Contre les Maladies, Ministère de la Sante, DRC.
  • Bennett RS; Integrated Research Facility at Fort Detrick.
  • Jahrling P; Integrated Research Facility at Fort Detrick.
  • Heymann DL; Integrated Research Facility at Fort Detrick.
  • Piot P; Integrated Research Facility at Fort Detrick.
  • Muyembe-Tamfum JJ; Chatham House Center on Global Health Security, London, UK.
  • Hensley LE; London School of Hygiene and Tropical Medicine, London, UK.
  • Simmons G; London School of Hygiene and Tropical Medicine, London, UK.
J Infect Dis ; 217(2): 223-231, 2018 01 04.
Article in En | MEDLINE | ID: mdl-29253164
ABSTRACT
The first reported outbreak of Ebola virus disease occurred in 1976 in Yambuku, Democratic Republic of Congo. Antibody responses in survivors 11 years after infection have been documented. However, this report is the first characterization of anti-Ebola virus antibody persistence and neutralization capacity 40 years after infection. Using ELISAs we measured survivor's immunological response to Ebola virus Zaire (EBOV) glycoprotein and nucleoprotein, and assessed VP40 reactivity. Neutralization of EBOV was measured using a pseudovirus approach and plaque reduction neutralization test with live EBOV. Some survivors from the original EBOV outbreak still harbor antibodies against all 3 measures. Interestingly, a subset of these survivors' serum antibodies could still neutralize live virus 40 years postinitial infection. These data provide the longest documentation of both anti-Ebola serological response and neutralization capacity within any survivor cohort, extending the known duration of response from 11 years postinfection to at least 40 years after symptomatic infection.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Disease Outbreaks / Hemorrhagic Fever, Ebola / Ebolavirus / Antibodies, Neutralizing / Antibodies, Viral Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Africa Language: En Journal: J Infect Dis Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Disease Outbreaks / Hemorrhagic Fever, Ebola / Ebolavirus / Antibodies, Neutralizing / Antibodies, Viral Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Africa Language: En Journal: J Infect Dis Year: 2018 Type: Article